- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05146765
Efficacy of a Digital Therapeutic for People With Dysarthria After Stroke
Efficacy of a Digital Therapeutic for People With Dysarthria After Stroke; Pilot Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A total of 40 patients with post-stroke dysarthria will be recruited and randomly divided into intervention and control groups.
Patients in the intervention group will be instructed to receive speech treatments including oro-motor exercise, phonation, articulation, resonance, syllable repetition, and reading exercise (App on mobile devices). Daily sessions will be provided during a 4-week period. Both groups will also receive treatment as usual. The aim of the study is to investigate the efficacy of mobile-based speech therapy in patients with dysarthria in the acute phase following stroke.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 07804
- Ewha womans university medical center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Neurologically stable, as determined by the clinician.
- Onset of stroke within four weeks prior to randomization.
- Diagnosis of dysarthria caused by stroke as confirmed by a stroke specialty neurologist.
- Maintains enough cognitive function to use the speech therapy application without problems, as determined by a Mini-Mental State Exam score of 26 ≥ within 1 month prior to randomization.
- Capable of walking or moving alone or with the assistance of a walking aid (e.g., walkers, canes, or wheelchairs).
- Must have intact vision, hearing, communication skills, and motor skills, as well as comprehension sufficient to proceed with assessment, as judged by the clinician.
Exclusion Criteria:
- Unable to measure articulatory or orofacial functions due to organic causes/lesions in articulatory and cervical structure.
- Has comorbid neurological conditions that, in the opinion of the investigator, could impair study participation, such as dementia (Alzheimer's disease, vascular dementia, Central Nervous System Infection [e.g., Human Immunodeficiency Virus, syphilis], Creutzfeld-Jacob disease, etc.), Pick's disease, Huntington's disease, or Parkinson's disease.
- Has a Mini-Mental State Exam score of 26 or below at the time of screening.
- Has a Clinical Dementia Rating score of 1 ≥ or a Global Deterioration Scale score of 3 ≥ at the time of screening.
- Received dementia treatment within 3 months of screening.
- Takes medication that may impact cognitive function during the clinical trial period.
- Co-medication is prohibited during the entire trial period for the following medications: drugs for dementia treatment, Central Nervous System stimulants, anticholinergics, tricyclic antidepressants, typical antipsychotics, and sleeping pills (excluding rapid-acting sleeping pills).
- Co-medication is permitted if continued use of the following medications has been at a stable dose for 2 months prior to randomization: atypical antipsychotics, anxiolytics, antidepressants (excluding tricyclic antidepressants), thyroid hormone, and rapid-acting sleeping pills.
- Is uneducated or illiterate.
- Has been diagnosed with a serious mental illness such as severe depression, schizophrenia, alcohol addiction, or drug addiction.
- Unable to use D-ST01 due to severe speech impairment, as determined by the clinician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
The intervention group will receive treatment as usual along with the speech therapy app.
|
Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
|
No Intervention: Control
The control group will receive treatment as usual only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Speech intelligibility
Time Frame: Baseline, 4weeks
|
Speech intelligibility is evaluated with a score of 0 (normal), 1 (intelligible, some differences noticeable), 2 (intelligible, noticeably different), 3 (intelligible with careful listening, some unintelligible), 4 (difficult to understand, many words unintelligible), 5 (usually unintelligible), or 6 (unintelligible).
|
Baseline, 4weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percent change in score on the Urimal Test of Articulation and Phonology 2 (UTAP2)
Time Frame: Baseline, 4weeks
|
he UTAP2, an essential tool for determining articulatory proficiency, will be employed to evaluate the Percentage of Consonants Correct (PCC), a crucial metric for identifying irregularities in articulation.
Study participants will be instructed to read all 30 words from the UTAP2 word-level test.
Following this, evaluators will calculate the PCC, expressed as a percentage, using the 94 consonants included in these words.
This methodology acknowledges that a PCC of 0% signifies lower articulatory accuracy, whereas a PCC of 100% reflects a higher level of precision.
|
Baseline, 4weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
National Institute of Health Stroke Scale (NIHSS)
Time Frame: Baseline, 4weeks
|
NIHSS will be used to assess stroke-related neurologic deficits.
The NIHSS scale is made up of 11 different elements that evaluate specific abilities; level of consciousness (LOC), best gaze, visual field, facial palsy, motor arm, motor leg, limb ataxia, sensory, best language, dysarthria, extinction, inattention.
The score ranges from 0 to 42; higher scores indicate more severe stroke symptoms.
|
Baseline, 4weeks
|
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline, 4weeks
|
The PHQ-9 is a nine-item self-reported questionnaire that is used to assess depressive symptoms.
The score ranges from 0 to 27, with lower scores indicating less depressive severity.
|
Baseline, 4weeks
|
Generalized Anxiety disorder-7
Time Frame: Baseline, 4weeks
|
GAD-7(Generalized Anxiety disorder-7) will be used to assess anxiety.
The GAD-7(Generalized Anxiety disorder-7) is a seven-item self-reported questionnaire that evaluates anxiety symptoms.
The score ranges from 0 to 21, with lower scores indicating lower anxiety symptoms.
|
Baseline, 4weeks
|
Euro Quality of Life (EQ-5D)
Time Frame: Baseline, 4weeks
|
EQ-5D will be used to assess the quality of life.
The EQ-5D is a self-report questionnaire that measures health-related quality of life.
The questionnaire consists of five dimensions: mobility, self-care, ordinary activities, discomfort, and mood state related to anxiety or depression.
The responses indicate three levels of severity ("no problems", "some problems", and "extreme problems") within each EQ-5D dimension.
|
Baseline, 4weeks
|
Modified Computer Self-Efficacy Scale (mCSES)
Time Frame: Baseline, 4weeks
|
mCSES will be used to assess participants' perceptions of self-efficacy with respect to using a computerized system.
The mCSES is a 10-item self-reported questionnaire.
The score ranges from 0 to 100; higher scores indicate a stronger sense of personal competence.
|
Baseline, 4weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tae-Jin Song, MD, PhD, Department of Neurology, Ewha University College of Medicine, Seoul, Republic of Korea
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D-ST01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysarthria as Late Effect of Stroke
-
Isra UniversityUnknownDysarthria as Late Effect of StrokePakistan
-
Ewha Womans University Seoul HospitalEwha Womans University Mokdong Hospital; National Rehabilitation Center, Seoul...Not yet recruitingDysarthria as Late Effect of Stroke
-
Ewha Womans University Seoul HospitalEwha Womans University Mokdong Hospital; National Rehabilitation Center, Seoul...RecruitingDysarthria as Late Effect of StrokeKorea, Republic of
-
Lone FornerDanish Cancer SocietyUnknownLate Effect of RadiationDenmark
-
Rennes University HospitalCompletedLeft-sided Hemiplegia Affecting Dominant Side as Late Effect of Cerebrovascular AccidentFrance
-
Far Eastern Memorial HospitalUnknownThoracic Neoplasms | Late Effect of RadiationTaiwan
-
Moustafa Mohammed AboueleaRecruitingEffect of Adding GnRHa as Luteal Phase Support in Antagonist ART CyclesEgypt
-
The Netherlands Cancer InstituteCompletedQuality of Life | Cancer | Lifestyle | Survivorship | Late EffectNetherlands
-
Islamabad Medical and Dental CollegeRecruitingEffect of Aloe Vera Gel as an Intracanal Medicament in Asymptomatic Periapical LesionsPakistan
-
Loma Linda UniversityCompletedHemiparesis as Late Effect of Cerebrovascular DiseaseUnited States
Clinical Trials on Mobile application
-
Mississippi State UniversityRecruiting
-
Mississippi State UniversityAssociation for contextual behavioral scienceNot yet recruitingHealth-Related BehaviorUnited States
-
George Washington UniversityMedia RezRecruiting
-
University of ReginaCompletedStress | Dementia | Caregiver BurdenCanada
-
University Hospitals Cleveland Medical CenterCompleted
-
Ankara Yildirim Beyazıt UniversityNot yet recruiting
-
University of CadizRecruiting
-
Boston Medical CenterBoston Medical Center Food KitchenWithdrawnDiabetes Mellitus, Type 2 | Pre DiabetesUnited States
-
Instituto de investigación e innovación biomédica...Completed
-
Oslo University HospitalDiakonhjemmet Hospital; South-Eastern Norway Regional Health AuthorityCompletedRheumatic Diseases | Chronic DiseaseNorway